Showing results (41-50 of 214) with videos related to
Sort By:
Pageof 22
Current Topics in Medicinal Chemistry|December 17, 2008
Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discoverySantiago Vilar, Giorgio Cozza, Stefano MoroMedicinal Research Reviews|June 16, 2009
How druggable is protein kinase CK2?Giorgio Cozza, Andrea Bortolato, Stefano MoroFrontiers in Pharmacology|July 31, 2025
Mapping the oxidative landscape in cystic fibrosis: methodological frontiers and applicationMichela Rubin, Ilaria Artusi, Giorgio CozzaBiopolymers|September 1, 2007
Elucidation of the ribonuclease A aggregation process mediated by 3D domain swapping: a computational approach reveals possible new multimeric structuresGiorgio Cozza, Stefano Moro, Giovanni GotteAnti-Cancer Agents in Medicinal Chemistry|October 16, 2008
Protein kinase CK2 inhibitors: emerging anticancer therapeutic agents?Andrea Bortolato, Giorgio Cozza, Stefano MoroPharmaceuticals (Basel, Switzerland)|June 27, 2025
Redox Imbalance in Cystic Fibrosis: The Multifaceted Role of Oxidative StressIlaria Artusi, Michela Rubin, Giorgio CozzaBiochemistry|August 30, 2011
Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancerRoberto Battistutta, Giorgio Cozza, Fabrice Pierre, et al.The Biochemical Journal|May 4, 2002
Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cellsMaria Ruzzene, Daniele Penzo, Lorenzo A PinnaThe FEBS Journal|January 13, 2017
From phosphoproteins to phosphoproteomes: a historical accountAndrea Venerando, Luca Cesaro, Lorenzo A PinnaMolecular and Cellular Biochemistry|July 16, 2008
A structural insight into CK2 inhibitionMarco Mazzorana, Lorenzo A Pinna, Roberto BattistuttaPageof 22